Eslicarbazepine acetate (ESL), sold under the brand names Aptiom and Zebinix among others, is an anticonvulsant medication approved for use in Europe and the United States as monotherapy or as additional therapy for partial-onset seizures epilepsy.
Similarly to oxcarbazepine, ESL behaves as a prodrug to (S)-(+)-licarbazepine. As such, their mechanisms of action are identical.